Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cellebrite DI Ltd. Market Cap
Based on ratings from 8 stock analysts, the Cellebrite DI Ltd. stock price is expected to increase by 11.14% in 12 months. This is calculated by using the average 12-month stock price forecast for Cellebrite DI Ltd.. The lowest target is $21 and the highest is $24. Please note analyst price targets are not guaranteed and could be missed completely.
CLBT is a stock in Technology which has been forecasted to be worth $22.42857 as an average. On the higher end, the forecast price is $24 USD by Jeff Van Rhee from Craig-Hallum and on the lower end CLBT is forecasted to be $21 by Mike Cikos from Needham.
These are the latest 20 analyst ratings of CLBT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mike Cikos Needham | Buy | $21 | Maintains | Nov 7, 2024 |
| Jeff Van Rhee Craig-Hallum | Buy | $24 | Maintains | Nov 7, 2024 |
| Brian Essex JP Morgan | Overweight | $22 | Maintains | Nov 7, 2024 |
| Jeff Van Rhee Craig-Hallum | Buy | $23 | Maintains | Sep 25, 2024 |
| Shaul Eyal TD Cowen | Buy | $23 | Maintains | Sep 23, 2024 |
| Tal Liani B of A Securities | Buy | $17 | Maintains | Aug 16, 2024 |
| Jamie Shelton Deutsche Bank | Buy | $18 | Maintains | Aug 16, 2024 |
| Jeff Van Rhee Craig-Hallum | Buy | $20 | Maintains | Aug 16, 2024 |
| Frank Takkinen Lake Street | Buy | $17 | Maintains | Aug 16, 2024 |
| Brian Essex JP Morgan | Overweight | $17 | Maintains | Aug 16, 2024 |
| Mike Cikos Needham | Buy | $17 | Maintains | Aug 16, 2024 |
| Brian Essex JP Morgan | Overweight | $15 | Maintains | Aug 14, 2024 |
| Mike Cikos Needham | Buy | $14 | Maintains | May 24, 2024 |
| Brian Essex JP Morgan | Overweight | $14 | Maintains | May 24, 2024 |
| Frank Takkinen Lake Street | Buy | $13 | Initiates | Apr 19, 2024 |
| Tal Liani B of A Securities | Buy | $13 | Maintains | Apr 1, 2024 |
| Jeff Van Rhee Craig-Hallum | Buy | $16 | Maintains | Apr 1, 2024 |
| Mike Cikos Needham | Buy | $13.5 | Maintains | Mar 28, 2024 |
| Jonathan Ho William Blair | Outperform | Upgrade | Mar 13, 2024 | |
| Tomer Zilberman B of A Securities | Buy | $12 | Upgrade | Feb 16, 2024 |
When did it IPO
2020
Staff Count
1,008
Country
Israel
Sector/Industry
Technology/Software - Infrastructure
CEO
Mr. Yossi Carmil
Market Cap
$4.34B
In 2023, CLBT generated $325.1M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CLBT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cellebrite (NASDAQ: CLBT) will participate in the UBS Global Technology and AI Conference, highlighting its role in digital investigative solutions for various sectors.
Why It Matters - Cellebrite's participation in the UBS Global Technology and AI Conference signals potential growth opportunities and investor interest in its digital solutions, impacting stock performance.
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cellebrite Endpoint Inspector Solutions are now generally available for use within RelativityOne, expanding their integration and accessibility for users.
Why It Matters - Cellebrite's integration with RelativityOne enhances its data analytics capabilities, potentially increasing demand for its solutions, which could boost revenue and stock value.
Thu, 14 Nov 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Cellebrite, a leader in AI, is retreating to a vital support level after a 65% price rally, making it a notable stock for investors to monitor.
Why It Matters - Cellebrite's pullback to a key support level after a significant rally indicates potential for future price stability or growth, attracting attention from investors seeking AI opportunities.
Mon, 11 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Cellebrite DI's stock has risen 160% since being rated a 'strong buy,' outperforming the S&P 500's 33%. Positive developments noted in its Q3 2024 earnings report.
Why It Matters - Cellebrite's 160% stock surge versus the S&P 500's 33% reflects strong market confidence and growth potential, making it a compelling option for investors focused on high returns.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Investors in the Technology Services sector may consider Nu Holdings Ltd. (NU) and Cellebrite DI Ltd. as potential stock options.
Why It Matters - The mention of Nu Holdings Ltd. and Cellebrite DI Ltd. highlights potential investment opportunities in the Technology Services sector, indicating growth or interest in these companies.
Fri, 08 Nov 2024
Sentiment - NEGATIVE
Source - Seeking Alpha
Summary - Cellebrite has a neutral rating due to premium valuation and risks from CEO transition and federal budget cuts, despite 27% revenue growth and strong product adoption.
Why It Matters - Cellebrite's premium valuation and leadership transition risks, coupled with potential federal budget cuts, create uncertainty despite strong revenue growth and product adoption.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
